Skip to content

Evaluation of Ayurvedic management on patients of Grahani Roga

A Clinical Study on the effect of Nagaradi Kwatha in the management of Grahani Roga with special reference to Malabsorption Syndrome

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/03/023729
Enrollment
60
Registered
2020-03-03
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K529- Noninfective gastroenteritis and colitis, unspecified

Interventions

Intervention1: Nagaradi Kwath: Nagaradi kwath 40 ml twice daily Intervention2: Nagaradi Kwath with pathyahara-vihara: Nagaradi kwath 40 ml twice daily alongwith instructions for pathyahara vihara Inte

Sponsors

Department of Kayacikitsa
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients willing to participate in the study. 2. Patients having the classical features of Grahani roga alongwith reduced appetite, tenesmus, and frequent passage of loose, mucoid stools. 4. Total duration of the illness less than one year.

Exclusion criteria

Exclusion criteria: 1. Patients not willing to participate in the study. 2. Patients of either sex below 30 year and above 65 years will be excluded from the study. 3. Patients with features of Sangraha grahani, Ghateeyantra grahani and evidence of malignancy, ulcerative colitis, Crohnâ??s disease, abdominal TB. 4. Total duration of the illness more than three years. 5. Patients on prolonged ( >6weeks) medication with corticosteroids, anti-depressants, anticholinergics, etc., or any other drugs that may have an influence on the outcome of the study. 6. Patients suffering from major systemic illness necessitating long term drug treatment Rheumatoid arthritis, tuberculosis, psycho-neuro-endocrinal disorders, etc. 7. Patients with concurrent serious hepatic disorder or renal disorders, severe pulmonary dysfunction, major cardiac problems or any other condition that may jeopardize the study. 8. Alcoholics and/or drug abusers. 9. History of hypersensitivity to the trial drug or any of its ingredients. 10. Pregnant/ lactating woman. 11. Patients who have completed participation in any other clinical trial during the past 6 months. 12. Any other conditions, which the principal investigator thinks may exclude the patient.

Design outcomes

Primary

MeasureTime frame
1. Disease specific Ayurvedic subjective parameters on VAS 2. Rome III criteria for diagnosis of IBS. Timepoint: 12 weeks duration divided into 3 follow up of 4 weeks.

Secondary

MeasureTime frame
2. Assessment of Agni status: By using Agni grading scale developed by Singh RH et al. 3. Assessment of Ama developed by Singh RH et al Timepoint: 12 weeks duration divided into 3 follow up of 4 weeks.

Countries

India

Contacts

Public ContactProf Rajendra Prasad

Institute of Medical Sciences, BHU

rajendraprasad051@gmail.com9411471910

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026